Loading…
Zevra Therapeutics, Inc. is projected to rise to $12.98 by 2027, a +36% move from its current price of $9.51. ZVRA is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 8/1/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Aug 2 | $9.22 | $9.52 | $9.82 | +0.06% |
| Aug 3 | $9.11 | $9.52 | $9.96 | +0.13% |
| Aug 4 | $9.02 | $9.53 | $10.06 | +0.19% |
| Aug 5 | $8.95 | $9.53 | $10.15 | +0.25% |
| Aug 6 | $8.89 | $9.54 | $10.24 | +0.31% |
| Aug 7 | $8.84 | $9.55 | $10.31 | +0.38% |
| Aug 8 | $8.79 | $9.55 | $10.38 | +0.44% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $8.79 | $9.55 | $10.38 | +0.44% |
| Week 2 | $8.53 | $9.59 | $10.79 | +0.88% |
| Week 3 | $8.34 | $9.64 | $11.13 | +1.32% |
| Week 4 | $8.19 | $9.68 | $11.43 | +1.77% |
| Week 5 | $8.07 | $9.72 | $11.71 | +2.21% |
| Week 6 | $7.96 | $9.76 | $11.97 | +2.66% |
| Week 7 | $7.87 | $9.81 | $12.23 | +3.11% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Zevra Therapeutics, Inc., a commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States. The company develops its products through Ligand Activated Technology platform.
Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 3 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase 3 clinical trial to treat narcolepsy. The company is developing Celiprolol, an investigational product candidate that is under Phase 3 clinical trial for the treatment of vascular Ehlers Danlos syndrome.
In addition, it offers AZSTARYS, a once-daily treatment for attention deficit and hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and MIPLYFFA for the treatment of niemann-pick disease type C, an ultra-rare neurodegenerative disease. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company's product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA.
The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. The company was incorporated in 2006 and is headquartered in Boston, Massachusetts.
Zevra Therapeutics, Inc. (ZVRA) is a healthcare company with a current price of $9.53 and a market capitalization of $563.07M. It ranks 2767 in market cap.
The multi-year forecast projects a bullish trajectory, with the average price gradually moving higher through 2035 and beyond, including a path from $9.53 in 2026 to $149.19 by 2050 and a maximum of $277.40 in 2050.
Forecast data for 2026 show min $8.31, avg $9.53, max $12.76 with a 0% ROI and NEUTRAL sentiment. From 2027 onward, the outlook shifts to bullish, with rising Avg prices across years and increasing ROI, culminating in 2050 with Avg $149.19, max $277.40, and ROI 1466.3%.
A major floor 36.7% below — a decisive break under it would weaken the trend.
Price is testing support right now (0.0% away) — a key level to hold.
The nearest ceiling, 55.1% above — a clean break opens room to run.
A major ceiling 73.5% above — clearing it would confirm fresh momentum.
Key ZVRA support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of ZVRA market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $9.67 | Sell | $9.87 | Sell |
| MA 10 | $10.70 | Sell | $10.57 | Sell |
| MA 20 | $12.11 | Sell | $11.44 | Sell |
| MA 50 | $12.19 | Sell | $11.80 | Sell |
| MA 100 | $11.13 | Sell | $11.28 | Sell |
| MA 200 | $10.11 | Sell | $10.51 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 28.73 | Buy |
| Stoch RSI (14) | 5.80 | Buy |
| CCI (20) | -116.75 | Sell |
| Williams %R (14) | -100.00 | Info |
| MACD (12,26,9) | -0.39 | Sell |
| ROC (12) | -26.62 | Sell |
| Bollinger %B (20,2) | 0.13 | Neutral |
| Stochastic %K (14) | 0.00 | Buy |
| TRIX (15) | -0.51 | Sell |
| Awesome (5,34) | -2.89 | Sell |
| Ultimate (7,14,28) | 19.57 | Buy |
| Momentum (10) | -3.26 | Sell |
| Aroon Osc (25) | -68.00 | Sell |
| Hull MA (9) | 9.14 | Buy |
| ADX (14) | 25.99 | Sell |
| ATR (14) | 0.40 | Info |
30-day technical picture (last 30 days): sentiment is NEUTRAL with RSI14 at 50. The SMA50 is $12.34 and the SMA200 is $10.14. The 30-day price range runs from $7.93 to $11.44.
In terms of clinical-like support and resistance, the indicated support is $12.03 and resistance is $14.75. The annualized volatility is 50%.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $8.31 | $9.51 | $12.63 | 0% | Neutral | |
| $10.21 | $12.98 | $17.54 | +36% | Bullish | |
| $12.17 | $15.99 | $22.55 | +68% | Bullish | |
| $15.03 | $20.31 | $29.58 | +114% | Bullish | |
| $15.93 | $22.06 | $33.03 | +132% | Bullish | |
| $15.33 | $21.70 | $33.28 | +128% | Bullish | |
| $17.93 | $25.90 | $40.59 | +172% | Bullish | |
| $19.18 | $28.27 | $45.16 | +197% | Bullish | |
| $21.92 | $32.91 | $53.50 | +246% | Bullish | |
| $27.41 | $41.89 | $69.23 | +340% | Bullish | |
| $34.31 | $56.87 | $100.65 | +498% | Bullish | |
| $69.22 | $132.39 | $258.62 | +12.9x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| August 2026 | $8.31 | $9.51 | $11.83 | +0.00% |
| September 2026 | $8.61 | $10.23 | $12.54 | +7.59% |
| October 2026 | $8.41 | $10.07 | $12.49 | -1.60% |
| November 2026 | $8.12 | $9.79 | $12.26 | -2.80% |
| December 2026 | $8.24 | $9.99 | $12.63 | +2.13% |
Click any year to see its month-by-month ZVRA forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
Zevra Therapeutics, Inc.'s 2026 outlook centres on $9.51, within a $8.31 to $12.63 range. That marks a 0% change versus current levels. Price action looks broadly range-bound.
By 2027, ZVRA could reach as high as $17.54, with a base case around $12.98 and support toward $10.21 — roughly +36% from $9.51. Buyers look set to stay in control over this stretch.
Expect ZVRA to range from $12.17 to $22.55 through 2028. The $15.99 average target implies a +68% move from current prices. That is up +23% on the projected 2027 average. Momentum favours further upside here.
The ZVRA price prediction for 2029 points to an average of $20.31 (low $15.03, high $29.58) — a potential gain of +114% on today's $9.51. Buyers look set to stay in control over this stretch.
In 2030, ZVRA is projected to trade between $15.93 and $33.03, averaging $22.06 — a potential gain of +132% from today's $9.51. That is up +9% on the projected 2029 average. Momentum favours further upside here.
Zevra Therapeutics, Inc.'s 2031 outlook centres on $21.70, within a $15.33 to $33.28 range. That is -2% versus the projected 2030 average. That marks a +128% change versus current levels. Buyers look set to stay in control over this stretch.
By 2032, ZVRA could reach as high as $40.59, with a base case around $25.90 and support toward $17.93 — roughly +172% from $9.51. Momentum favours further upside here.
Expect ZVRA to range from $19.18 to $45.16 through 2033. The $28.27 average target implies a +197% move from current prices. That is up +9% on the projected 2032 average. Buyers look set to stay in control over this stretch.
The ZVRA price prediction for 2034 points to an average of $32.91 (low $21.92, high $53.50) — a potential gain of +246% on today's $9.51. Momentum favours further upside here.
In 2035, ZVRA is projected to trade between $27.41 and $69.23, averaging $41.89 — a potential gain of +340% from today's $9.51. That is up +27% on the projected 2034 average. Buyers look set to stay in control over this stretch.
Zevra Therapeutics, Inc.'s 2040 outlook centres on $56.87, within a $34.31 to $100.65 range. That is up +36% on the projected 2035 average. That marks a +498% change versus current levels. Momentum favours further upside here.
By 2050, ZVRA could reach as high as $258.62, with a base case around $132.39 and support toward $69.22 — roughly +12.9x from $9.51. Buyers look set to stay in control over this stretch.
Investing $1,000 in ZVRA today (≈ 105.152471 ZVRA) could be worth
$13,921.36
+$12,921.36 (+1292%) by 2050 · US Dollar
Based on the average projected ZVRA price of $132.39 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in ZVRAwould be worth at today's price.
$1,000 invested in ZVRA on Jul 31, 2025 (≈ 90.009004 ZVRA) would be worth
$855.99
-$144.01 (-14.4%) today · 0.86× · US Dollar
Based on a ZVRA entry price of $11.11 vs. today's $9.51.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $9.52 | $998.43 | -0.2% |
| 1 month ago | $13.81 | $688.63 | -31.1% |
| 3 months ago | $10.07 | $944.39 | -5.6% |
| 6 months ago | $9.36 | $1,016.03 | +1.6% |
| 1 year ago | $11.11 | $855.99 | -14.4% |
| All time (5.0y) ago | $10.3 | $923.3 | -7.7% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our ZVRA forecast.
Our base-case forecast reaches $19.00 around 2029.
Implied market cap at $19.00: $1.12B
The multi-year forecast shows a bullish stance starting in 2027 and continuing through 2050. The 2026 average is $9.53 with a min of $8.31 and a max of $12.76 (ROI 0%, sentiment NEUTRAL).
From 2027 onward, the model envisions steady upside: 2027 avg $13.24; 2028 avg $16.51; 2029 avg $20.86; 2030 avg $22.76 (ROI 138.9%, sentiment BULLISH); 2031 avg $23.15; 2032 avg $27.93; 2033 avg $30.55; 2034 avg $35.89; 2035 avg $45.42 (ROI 376.8%, sentiment BULLISH).
Further out, 2040 avg $64.27 (ROI 574.8%, sentiment BULLISH) and 2050 avg $149.19 with a max of $277.40 (ROI 1466.3%, sentiment BULLISH). These figures illustrate a substantial long-term upside but are estimates and not guarantees.
Tap a question to reveal the answer.
Avg $22.76; min $16.83; max $33.18; ROI 138.9%; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with rising Avg prices (13.24 in 2027, 16.51 in 2028, 20.86 in 2029, 22.76 in 2030, 23.15 in 2031, 27.93 in 2032, 30.55 in 2033, 35.89 in 2034, 45.42 in 2035, 64.27 in 2040, 149.19 in 2050) and increasing ROI (39% in 2027, 73.3% in 2028, 119% in 2029, 138.9% in 2030, 143.1% in 2031, 193.2% in 2032, 220.7% in 2033, 276.9% in 2034, 376.8% in 2035, 574.8% in 2040, 1466.3% in 2050). These are estimates and not guarantees.
The max forecast price by 2050 is $277.40, which is below $300.
Current price is $9.53; Market cap is $563.07M.
The 30-day range is $7.93 to $11.44.
Zevra Therapeutics, Inc. Community Discussion
0Share your Zevra Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.